microRNAs: Potential glioblastoma radiosensitizer by targeting radiation-related molecular pathways

Bahreyni-Toossi, Mohammad-Taghi; Dolat, Elham; Khanbabaei, Hashem; Zafari, Navid; Azimian, Hosein

doi:10.1016/j.mrfmmm.2019.111679

Cited by 21 publications

(11 citation statements)

References 91 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MiRNAs regulate gene expression by targeting mRNAs, and after directly binding to the complementary 3′UTR site of the target mRNA [ 3 ], miRNA acts as an mRNA silencer. MiRNAs can regulate multiple target mRNAs involved in resistance by controlling many biological processes including apoptosis, DNA damage repair, proliferation, cell cycle, senescent, invasiveness, and angiogenesis [ 16 ]. Generally, mRNA acts in two possible ways in mRNA silencing: mRNA degradation or translation inhibition through the actions of the RNA-induced silencing complex (RISC).…”

Section: Micrornasmentioning

confidence: 99%

“…An important reason for the inadequate response of GB to radiotherapy is radioresistance. MicroRNAs (miRNAs) are important regulatory molecules that can effectively control glioblastoma by affecting signal transduction pathways [ 16 ]. MiRNAs act as diagnostic biomarkers in brain tumors and are used for tumor treatment [ 12 ].…”

Section: Microrna In Glioblastomamentioning

confidence: 99%

“…(4) Tumor suppressor miRNAs such as miR-34, miR-128, and miR-181 are down-regulated in GB cells. The up-regulation of miR-34 could enhance cellular reactive oxygen species (ROSs), increase radio sensitivity, and inhibit cell viability [ 16 ]. MicroRNA-128 overexpression could inhibit GB cell growth and enhance cell radio sensitivity through the down-regulation of BMI1.…”

Section: Microrna In Glioblastomamentioning

confidence: 99%

“…MicroRNA-128 overexpression could inhibit GB cell growth and enhance cell radio sensitivity through the down-regulation of BMI1. Finally, miR-181 inhibits Bcl-2 and leads to the down-regulation of glioblastoma [ 16 ] ( Figure 2 ).…”

Section: Microrna In Glioblastomamentioning

confidence: 99%

See 3 more Smart Citations

Glioblastoma and MiRNAs

Ahmed

Castresana

Shahi

2021

Cancers

View full text Add to dashboard Cite

Glioblastoma (GB) is one of the most common types of lethal brain tumors. Although several treatment options are available including surgery, along with adjuvant chemo and radiotherapy, the disease has a poor prognosis and patients generally die within 14 months of diagnosis. GB is chemo and radio resistant. Thus, there is a critical need for new insights into GB treatment to increase the chance of therapeutic success. This is why microRNA (miRNA) is being potentially considered in the diagnosis and treatment of glioblastoma. The objective of our review is to provide a holistic picture of GB up-regulated and down-regulated miRNA, in relationship with the expression of other genes, cell signaling pathways, and their role in GB diagnosis and treatment. MiRNA treatment is being considered to be used against GB together with radiotherapy and chemotherapy. Moreover, the use of miRNA as a diagnostic tool has also begun. Knowing that miRNAs are isolated in almost all human body fluids and that there are more than 3000 miRNAs in the human genome, plus the fact that each miRNA controls hundreds of different mRNAs, there is still much study needed to explore how miRNAs relate to GB for its proliferation, progression, and inhibition.

show abstract

Section: Micrornasmentioning

confidence: 99%

Section: Microrna In Glioblastomamentioning

confidence: 99%

Section: Microrna In Glioblastomamentioning

confidence: 99%

Section: Microrna In Glioblastomamentioning

confidence: 99%

See 2 more Smart Citations

Glioblastoma and MiRNAs

Ahmed

Castresana

Shahi

2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Resistance has been linked to this stem fate, so research has been done in adult glioblastoma CSCs to push the stem cells to a more differentiated, and therefore more sensitive fate (38,39). PARP inhibitors, high-Z metal nanoparticles, PI3K inhibitors, DNA repair inhibitors, pimozide, CBL0137, various microRNAs, and many other therapeutic techniques have been shown to sensitize glioblastoma to irradiation (39)(40)(41)(42)(43). PARP inhibitors have been shown in glioblastoma to decrease the CSC frequency in vivo, leading to a higher percentage of non-CSCs in the tumor.…”

Section: Csc Genetic Changes In Pediatric Brain Tumorsmentioning

confidence: 99%

Cancer Stem Cells in Pediatric Brain Tumors

Tallman

Zalenski

Venere

2021

Gliomas

View full text Add to dashboard Cite

Cancer stem cells are a subpopulation of tumor cells that have the ability to self-renew, initiate tumors in model systems, and differentiate into noncancer stem cells. They are also resistant to current standard of care treatments, such as radiotherapy and chemotherapy. Due to these properties, cancer stem cells contribute to tumor progression and recurrence and need to be inclusively targeted with therapeutic paradigms used in the clinical setting. This chapter covers the most up-to-date published information on cancer stem cells in the context of pediatric brain tumors. The characteristics of pediatric brain tumor cancer stem cells, including resistance mechanisms and differential genetic regulation that allow for the stem like phenotype, are presented. The current research on cancer stem cells in medulloblastoma, ependymoma, diffuse intrinsic pontine glioma, and pediatric gliomas as well as potential approaches that are being developed to target cancer stem cells are highlighted. Challenges in targeting cancer stem cells in the pediatric patient population are also discussed.

show abstract

Nanoparticles Mediated the Diagnosis and Therapy of Glioblastoma: Bypass or Cross the Blood–Brain Barrier

Song

Qian

2023

Small

View full text Add to dashboard Cite

Glioblastoma is one of the most aggressive central nervous system malignancies with high morbidity and mortality. Current clinical approaches, including surgical resection, radiotherapy, and chemotherapy, are limited by the difficulty of targeting brain lesions accurately, leading to disease recurrence and fatal outcomes. The lack of effective treatments has prompted researchers to continuously explore novel therapeutic strategies. In recent years, nanomedicine has made remarkable progress and expanded its application in brain drug delivery, providing a new treatment for brain tumors. Against this background, this article reviews the application and progress of nanomedicine delivery systems in brain tumors. In this paper, the mechanism of nanomaterials crossing the blood‐brain barrier is summarized. Furthermore, the specific application of nanotechnology in glioblastoma is discussed in depth.

show abstract

microRNAs: Potential glioblastoma radiosensitizer by targeting radiation-related molecular pathways

Cited by 21 publications

References 91 publications

Glioblastoma and MiRNAs

Glioblastoma and MiRNAs

Cancer Stem Cells in Pediatric Brain Tumors

Nanoparticles Mediated the Diagnosis and Therapy of Glioblastoma: Bypass or Cross the Blood–Brain Barrier

Contact Info

Product

Resources

About